 A recent paper published in Cancer Research estimates that one-third of all cancer patients have at least one comorbidity. That number can increase depending on the specific cancer diagnosis. So broadening the scope of accepted patients would help figure out how these drugs interact with other health issues, as well as increase participation rates.